Table 2.
Treatment details and outcomes of patients receiving additional radiotherapy
| Pt | Type of RT | TD (Gy)/fractions | Subseq Tx after RT | TLR/OR | Site(s) of PD | Subseq Tx after PD | TI to LP (months) | TI to PFS (months) | TI to OS (months) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PBT | 66/10 | Ate/Beva | CR/CR | IHD/EHD | RT→Ate/Beva→TACE→Lenva | - | 4.8 | DWD 14.9 |
| 2 | PBT | 35/10 | Ate/Beva | PR/SD | IHD | Ate/Beva→Ate/Lenva | - | 4.0 | DWD 13.5 |
| 3 | IMRT | 35/10 | Ate/Beva | PR/SD | - | - | - | - | DWD 13.7 |
| 4 | IMRT | 35/10 | Ate/Beva | SD/SD | IHD | - | - | 2.8 | DWD 4.2 |
| 5 | IMRT | 33/10 | Ate/Beva | SD/SD | EHD | RT→Ate/Beva→SR→Lenva | 5.9 | 3.9 | DWD 14.8 |
| 6 | IMRT | 66/10 | Ate/Beva | PR/PD | IHD/EHD | - | - | 2.6 | DWD 16.1 |
| 7 | IMRT | 33/10 | Ate/Beva | PR/PR | EHD | Nivo + GP | 7.2 | 7.2 | AWD 14.2 |
Pt, patient; RT, radiotherapy; TD, total radiation dose; Subseq, subsequent; Tx, treatment; TLR, targeted lesion(s) response; OR, overall response; PD, progressive disease; TI, time interval; LP, local progression; PFS, progression free survival; OS, overall survival; PBT, proton beam therapy; Ate, atezolizumab; Beva, bevacizumab; CR, complete response; IHD, intrahepatic disease other than the targeted lesion(s); EHD, extrahepatic disease other than the targeted lesion(s); TACE, transarterial chemoemboization; Lenva, lenvatinib; DWD, death with disease; PR, partial response; SD, stable disease; IMRT, intensity modulated radiotherapy; Nivo, nivolumab; GP, gemcitabine and cisplatin; AWD, alive with disease.